Drug delivery from engineered organisms and nanocarriers as monitored by multimodal imaging technologies

In recent years, while the research budget and development times increased for different phases of drug development, the number of clinically approved new medicines declined. In fact, many promising drug candidates failed to demonstrate their full therapeutic potential <em>in vivo</em>....

Full description

Bibliographic Details
Main Authors: Daniel Calle, Duygu Yilmaz, Sebastian Cerdan, Armagan Kocer
Format: Article
Language:English
Published: AIMS Press 2017-03-01
Series:AIMS Bioengineering
Subjects:
Online Access:http://www.aimspress.com/Bioengineering/article/1322/fulltext.html
Description
Summary:In recent years, while the research budget and development times increased for different phases of drug development, the number of clinically approved new medicines declined. In fact, many promising drug candidates failed to demonstrate their full therapeutic potential <em>in vivo</em>. Reasons for unfavorable outcome include some intrinsic properties of drugs, like biodegradation, solubility, and systemic toxicity, as well as the ways in which they are administered or the time elapsed until therapeutic efficiency is demonstrated. Therefore, to develop the full therapeutic potential of drug candidates <em>in vivo</em>, there is a need for advanced drug delivery systems that would carry the drug specifically to the target and release it there at desired concentrations. In addition, there is a requirement for non-invasive biomedical imaging technologies allowing for rapid and sensitive evaluations of drug performance <em>in vivo</em>. This review will present recent developments in bioengineered drug delivery systems, highlighting the biomedical imaging tools needed to evaluate the success of drug delivery strategies.
ISSN:2375-1495